Disease · MONDO_0005131
cervical carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cervical carcinoma. Diseases, record MONDO_0005131. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005131
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of the cervix, cancer of the uterine cervix, cancer of uterine cervix, carcinoma cervix uteri, carcinoma of cervix, carcinoma of cervix uteri, carcinoma of the cervix, carcinoma of the cervix uteri, carcinoma of the uterine cervix, carcinoma of uterine cervix, cervix carcinoma, cervix uteri carcinoma, uterine cervix carcinoma
- Open Targets
Drugs69
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 35 | 35 | 35 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| TOPOTECAN | CHEMBL84 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NELFINAVIR | CHEMBL584 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOPOTECAN HYDROCHLORIDE | CHEMBL1607 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 69
See all 69 drugsTargets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 5 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PARP1 | PARP 1, 2 and 3 | 4 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | Phase 2 | https://conductscience.org/library/genes/142 | Drugs and targets |
| PARP2 | PARP 1, 2 and 3 | 4 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/10038 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 4 | DNA topoisomerase I inhibitor | Phase 3 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 76
See all 76 targetsTrials70
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00191100 | Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix | Phase 3 | 515 | 2009-05-25 | Cancer of Cervix | CISPLATIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00064077 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | Phase 3 | 513 | 2018-08-28 | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer | CISPLATIN, GEMCITABINE, PACLITAXEL, TOPOTECAN, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | Phase 3 | 452 | 2016-05-24 | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer | BEVACIZUMAB, CISPLATIN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer | Phase 3 | 402 | 2017-07-02 | Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer | CISPLATIN, TIRAPAZAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00770874 | Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer | Phase 3 | 375 | 2019-06-21 | Cervical Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | Phase 3 | 236 | 2024-11-06 | Cervical Cancer | CARBOPLATIN, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | Phase 2 | 228 | 2011-03-14 | Neoplasms, Uterine Cervix, Metastatic Cervical Cancer | LAPATINIB, PAZOPANIB | Its record names the disease | ClinicalTrials.gov |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | Phase 2/3 | 101 | 2024-11-29 | Cervical Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00101192 | Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | Phase 2 | 76 | 2014-03-17 | Cervical Cancer | CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Phase 1/2 | 76 | 2025-03-17 | Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor | ETIGILIMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 70
See all 70 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Concurrent Cisplatin and Radiation vs Concurrent Cisplatin, Tirapazamine and Radiation: serious adverse events | 42 of 190 | 65 of 180 | 370 | NCT00262821 | Trial comparisons |
| S-1 + Cisplatin (Arm A) vs Cisplatin (Arm B): deaths from any cause | 7 of 188 | 3 of 175 | 363 | NCT00770874 | Trial comparisons |
| S-1 + Cisplatin (Arm A) vs Cisplatin (Arm B): serious adverse events | 72 of 188 | 34 of 175 | 363 | NCT00770874 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: deaths from any cause | 17 of 109 | 13 of 103 | 212 | NCT00980954 | Trial comparisons |
| Arm I: Cisplatin/Radiation Therapy vs Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel: serious adverse events | 14 of 107 | 25 of 101 | 208 | NCT00980954 | Trial comparisons |
| Lapatinib Monotherapy vs Pazopanib Monotherapy: Clinical Benefit Response | 7 of 78 | 15 of 74 | 152 | NCT00430781 | Trial comparisons |
| Lapatinib Monotherapy vs Pazopanib Monotherapy: Response | 4 of 78 | 7 of 74 | 152 | NCT00430781 | Trial comparisons |
| PET-Guided Bone Marrow-Sparing IMRT vs IMRT: Progression-free Survival | 46 of 46 | 55 of 55 | 101 | NCT01554397 | Trial comparisons |
| IMRT vs PET-Guided Bone Marrow-Sparing IMRT: deaths from any cause | 0 of 55 | 0 of 46 | 101 | NCT01554397 | Trial comparisons |
| IMRT Arm (Phase II) vs PET-Guided BMS-IMRT (Phase II): Primary Event (Acute Hematologic or GI Toxicity) | 55 of 55 | 46 of 46 | 101 | NCT01554397 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005131
GET https://conductscience.org/api/diseases/v1/MONDO_0005131/drugs?page=2